Akriti Jain, MD, discussed how emerging data on non-ABL1 mutations is reshaping chronic myeloid leukemia management.

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...

Leukemia & Lymphoma Society President and CEO, Dr. E. Anders Kolb, recently made a visit to the local team and shared his ...

When Dr. Filippo Milano left his home in Italy to study medicine in Seattle in 2008, it was supposed to be for six months, ...

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses ...

Learn more about whether Jazz Pharmaceuticals plc or Novo Nordisk A/S is a better investment based on AAII's A+ Investor ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...

Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm ...

The study builds on a small body of previous research, but Colorado’s oil and gas industry strongly disputes the findings.

Here's how. Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental Despite medical advances, heart disease has remained the leading cause of death in the U.S. for more than a ...